[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1208875A1 - Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3 - Google Patents

Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3

Info

Publication number
HK1208875A1
HK1208875A1 HK15109544.5A HK15109544A HK1208875A1 HK 1208875 A1 HK1208875 A1 HK 1208875A1 HK 15109544 A HK15109544 A HK 15109544A HK 1208875 A1 HK1208875 A1 HK 1208875A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
compounds
methods
ubiquitin ligase
targeted proteins
Prior art date
Application number
HK15109544.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧克瑞武茲
‧巴克利
‧丘利
‧喬根森
‧加賴斯
‧萬莫勒
‧古斯塔夫森
‧迪
‧米歇爾
‧霍耶
‧羅斯
‧哈靈
‧史密斯
‧米亞赫
‧坎波斯
‧勒
Original Assignee
Univ Yale
Glaxosmithkline Intellectual Property Dev
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Glaxosmithkline Intellectual Property Dev, Cambridge Entpr Ltd filed Critical Univ Yale
Publication of HK1208875A1 publication Critical patent/HK1208875A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
HK15109544.5A 2012-01-12 2015-09-29 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3 HK1208875A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585769P 2012-01-12 2012-01-12
PCT/US2013/021136 WO2013106643A2 (en) 2012-01-12 2013-01-11 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase

Publications (1)

Publication Number Publication Date
HK1208875A1 true HK1208875A1 (en) 2016-03-18

Family

ID=48782088

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109544.5A HK1208875A1 (en) 2012-01-12 2015-09-29 Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3

Country Status (12)

Country Link
US (3) US10730862B2 (ja)
EP (2) EP3608317A1 (ja)
JP (5) JP2015508414A (ja)
KR (4) KR20240096553A (ja)
CN (2) CN104736569A (ja)
AU (5) AU2013207900B2 (ja)
BR (1) BR112014017095A2 (ja)
CA (1) CA2861066C (ja)
HK (1) HK1208875A1 (ja)
MX (2) MX358660B (ja)
RU (1) RU2666530C2 (ja)
WO (1) WO2013106643A2 (ja)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130124291A (ko) 2010-07-02 2013-11-13 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체
SG186820A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht- 2 -ylacetic acid derivatives to treat aids
WO2012045018A1 (en) 2010-09-30 2012-04-05 St. Jude Children's Research Hospital Aryl-substituted imidazoles
PT2699558T (pt) 2011-04-21 2016-12-29 Gilead Sciences Inc Compostos de benzotiazole e a sua utilização farmacêutica
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
EP2800738B1 (en) * 2012-01-06 2020-04-08 Novartis AG Heterocyclic compounds and methods for their use
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2013159064A1 (en) 2012-04-20 2013-10-24 Gilead Sciences, Inc. Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
GB201311910D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014187777A1 (en) * 2013-05-21 2014-11-27 Mediapharma S.R.L. Novel inhibitors of pvhl-elongin c binding
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
RU2738833C9 (ru) * 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2015171591A1 (en) 2014-05-05 2015-11-12 Board Of Trustees Of The University Of Arkansas COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
WO2015184383A1 (en) * 2014-05-29 2015-12-03 St. Jude Children's Research Hospital Aryl-substituted imidazoles and methods of making and using same
EP3177144A4 (en) 2014-07-22 2018-01-24 Bioventures, LLC. Compositions and methods for selectively depleting senescent cells
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016045115A1 (zh) * 2014-09-28 2016-03-31 姜凡 Hiv-1整合酶抑制剂
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
EP3247708A4 (en) * 2015-01-20 2018-09-12 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
GB201504314D0 (en) * 2015-03-13 2015-04-29 Univ Dundee Small molecules
EP4414369A3 (en) * 2015-03-18 2024-10-16 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
JP6708661B2 (ja) 2015-03-30 2020-06-10 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
JP6873433B2 (ja) * 2015-06-04 2021-05-19 アルヴィナス・オペレーションズ・インコーポレイテッド タンパク質分解のイミド系修飾因子および関連の使用方法
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
JP6954619B2 (ja) * 2015-06-19 2021-10-27 学校法人東京理科大学 タンパク質分解誘導タグ及びその用途
CN105085620B (zh) * 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
MX2018000360A (es) * 2015-07-10 2018-06-11 Arvinas Inc Moduladores basados en mdm2 de proteolisis y metodos de uso asociados.
MX2018000471A (es) * 2015-07-13 2018-04-10 Arvinas Inc Moduladores de proteolisis basados en alanina y metodos de uso asociados.
WO2017009650A1 (en) * 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
EP3331906A1 (en) 2015-08-06 2018-06-13 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation
WO2017030814A1 (en) * 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
KR20220082095A (ko) 2015-10-30 2022-06-16 팀버 파마슈티칼스 엘엘씨 이소트레티노인 제형 및 이의 용도 및 사용 방법
CN108366992A (zh) 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法
GB201522768D0 (en) * 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
WO2017180417A1 (en) * 2016-04-12 2017-10-19 The Regents Of The University Of Michigan Bet protein degraders
US10781205B2 (en) 2016-04-20 2020-09-22 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
JP6936498B2 (ja) * 2016-04-21 2021-09-15 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アポトーシス性Ｂｃｌ−２ファミリータンパク質の分解を誘導する化合物及びその使用
CA3021358A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
EP3445760B1 (en) * 2016-04-22 2022-02-23 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
CN107305202B (zh) * 2016-04-22 2020-04-17 北京睿创康泰医药研究院有限公司 分析甲磺酸乐伐替尼及其制剂杂质的hplc方法及杂质作参比标准的用途
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN105943526B (zh) * 2016-05-18 2018-08-14 上海交通大学医学院附属上海儿童医学中心 Pd0325901在维持动脉导管开放中的应用
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
KR101825065B1 (ko) * 2016-05-24 2018-02-05 한국화학연구원 Alk 단백질의 분해를 유도하는 약학적 조성물 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
GB201610156D0 (en) * 2016-06-10 2016-07-27 Otsuka Pharma Co Ltd Cliptac compositions
GB201610147D0 (en) * 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
CA3025805A1 (en) * 2016-06-23 2017-12-28 James Bradner Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
EP3474900A4 (en) * 2016-06-23 2020-03-11 Dana-Farber Cancer Institute, Inc. DEGRADATION OF PROTEIN 9 (BRD9) CONTAINING BROMANOMAIN BY CONJUGATING BRD9 INHIBITORS WITH E3 LIGASE LIGAND AND METHOD FOR USE THEREOF
CN108495618B (zh) 2016-07-12 2019-08-16 冰洲石生物科技公司 新的化合物及其用途
CN106279120A (zh) * 2016-07-15 2017-01-04 谢阳 一种n‑芳基氨基甲酰基脯氨酸类化合物及其药物组合物和应用
CA3034326A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
CN106318920B (zh) * 2016-09-14 2019-10-11 中国科学院天津工业生物技术研究所 黄酮-6-羟化酶及其在灯盏乙素合成中的应用
GB2554071A (en) * 2016-09-14 2018-03-28 Univ Dundee Small molecules
ES2975558T3 (es) 2016-09-15 2024-07-09 Arvinas Inc Derivados de indol como degradantes de receptor de estrógeno
US12129248B2 (en) 2016-09-26 2024-10-29 Dana-Farber Cancer Institute, Inc. Chromobox protein inhibitors and uses thereof
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
JP6899993B2 (ja) * 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
MX2019004278A (es) 2016-10-11 2019-08-05 Arvinas Inc Compuestos y metodos para la degradacion dirigida del receptor de angrogenos.
EA201991071A1 (ru) 2016-10-28 2019-11-29 Композиции и способы для лечения ezh2-опосредованного рака
KR20230127371A (ko) 2016-11-01 2023-08-31 아비나스 오퍼레이션스, 인코포레이티드 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
CN106749060B (zh) * 2016-11-11 2019-07-23 湖北龙翔药业科技股份有限公司 一种帕托珠利的精制方法
BR112019009565A2 (pt) * 2016-11-15 2019-10-08 Univ Tokyo Science Found método de avaliação da cinética molecular e método de rastreamento
CN110035775A (zh) 2016-11-15 2019-07-19 学校法人东京理科大学 Ras蛋白分解诱导分子和药物组合物
US11007269B2 (en) 2016-11-15 2021-05-18 Tokyo University Of Science Foundation P53 degradation inducing molecule and pharmaceutical composition
JP7038712B2 (ja) * 2016-11-22 2022-03-18 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤のｅ３リガーゼリガンドとのコンジュゲーションによるｂｔｋの分解および使用法
CN118834201A (zh) 2016-12-01 2024-10-25 阿尔维纳斯运营股份有限公司 作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
US11541051B2 (en) 2016-12-08 2023-01-03 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
US10954210B2 (en) 2016-12-08 2021-03-23 Hangzhou Solipharma Co., Ltd. Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
IL294423B2 (en) * 2016-12-23 2024-01-01 Univ Yale Compounds and methods for targeted reduction of rapidly accelerated polypeptide fibrosarcoma
MX2019007646A (es) * 2016-12-23 2019-09-06 Arvinas Operations Inc Moleculas quimericas dirigidas a la proteolisis del egfr y metodos asociados de uso.
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN106749513A (zh) * 2017-01-23 2017-05-31 中国药科大学 基于vhl配体诱导bet降解的双功能分子及其制备和应用
US10604506B2 (en) 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
IL312367A (en) * 2017-01-31 2024-06-01 Arvinas Operations Inc Servalon ligands and bifunctional compounds containing them
AU2018219292B2 (en) * 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHIMERIC ANTIGEN RECEPTORS
CA3059671A1 (en) * 2017-04-14 2018-10-18 University Of Dundee Small molecules
JP2020518660A (ja) * 2017-04-28 2020-06-25 クォーツ セラピューティクス，インコーポレイティド Ｒａｆ分解性結合体化合物
CN108976278B (zh) * 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
JP2020523319A (ja) * 2017-06-07 2020-08-06 シルバーバック セラピューティックス インコーポレイテッド 免疫調節化合物の抗体コンジュゲートおよびその使用
CA3060372C (en) * 2017-06-09 2022-04-05 Dana-Farber Cancer Institute, Inc. Improved methods for generating small molecule degraders and dimerizers
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
MX2019015402A (es) 2017-06-22 2020-07-20 Catalyst Biosciences Inc Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.
CA3066518A1 (en) 2017-06-26 2019-01-03 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
JP2020528918A (ja) 2017-07-28 2020-10-01 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． アンドロゲン受容体の標的化分解のための化合物および方法
EP3668976A1 (en) * 2017-08-18 2020-06-24 Cambridge Enterprise Limited Modular binding proteins
CN109422751B (zh) * 2017-09-03 2022-04-22 上海美志医药科技有限公司 一类具有降解酪氨酸蛋白激酶jak3活性的化合物
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
EP3679028A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Dihydroquinolinones
CN111315735B (zh) 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
CA3075669A1 (en) * 2017-09-13 2019-03-21 Amgen Inc. Bisamide sarcomere activating compounds and uses thereof
IL273432B (en) 2017-09-22 2022-09-01 Kymera Therapeutics Inc Protein compounds and their uses
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071144A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
KR102129367B1 (ko) 2017-10-20 2020-07-03 한국화학연구원 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
EP3706737A4 (en) 2017-11-10 2021-10-20 The Regents of the University of Michigan ASH11 INHIBITORS AND METHOD OF TREATING THEREOF
CN111372585A (zh) 2017-11-16 2020-07-03 C4医药公司 用于靶蛋白降解的降解剂和降解决定子
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
JP2021014409A (ja) * 2017-11-21 2021-02-12 京都薬品工業株式会社 タンパク質結合性薬物
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CN109912655B (zh) * 2017-12-13 2021-12-10 上海科技大学 Alk蛋白降解剂及其抗肿瘤应用
EP3728251A1 (en) 2017-12-18 2020-10-28 F. Hoffmann-La Roche AG Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc IRAK joints and used in them
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
JP7385284B2 (ja) 2018-01-22 2023-11-22 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー 癌処置のためのｂｃｌ－２タンパク質分解剤
WO2019148055A1 (en) 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use
TW201945357A (zh) 2018-02-05 2019-12-01 瑞士商赫孚孟拉羅股份公司 化合物
US20210261538A1 (en) * 2018-02-22 2021-08-26 Icahn School Of Medicine At Mount Sinai Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use
CN112154146A (zh) 2018-03-06 2020-12-29 西奈山伊坎医学院 丝氨酸苏氨酸激酶(akt)降解/破坏化合物和使用方法
CN110240629B (zh) * 2018-03-09 2023-10-03 上海科技大学 蛋白降解靶向bcr-abl化合物及其抗肿瘤应用
EP3765026A4 (en) 2018-03-10 2021-12-22 Yale University BTK PROTEOLYSIS MODULATORS AND METHODS FOR USE
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
WO2019183600A1 (en) 2018-03-23 2019-09-26 The Regents Of The University Of California Methods and compounds for targeted autophagy
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
SG11202008898UA (en) * 2018-04-01 2020-10-29 Arvinas Operations Inc Brm targeting compounds and associated methods of use
WO2019195609A2 (en) 2018-04-04 2019-10-10 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
WO2019199816A1 (en) 2018-04-13 2019-10-17 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
US11998606B2 (en) 2018-04-13 2024-06-04 Board Of Regents, The University Of Texas System Compounds and methods for selective proteolysis of glucocorticoid receptors
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
EP3556760A1 (en) 2018-04-19 2019-10-23 F. Hoffmann-La Roche AG Spiro compounds
TWI813666B (zh) * 2018-04-20 2023-09-01 大陸商四川科倫博泰生物醫藥股份有限公司 一種多功能化合物、其製備方法及其在醫藥上的應用
WO2019218904A1 (zh) * 2018-05-18 2019-11-21 四川科伦博泰生物医药股份有限公司 非天然氨基酸类衍生物、其制备方法及用途
US12084423B2 (en) 2018-05-18 2024-09-10 Bioventures, Llc Piperlongumine analogues and uses thereof
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
WO2019238886A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting usp14
WO2019238817A1 (en) 2018-06-13 2019-12-19 University Of Dundee Bifunctional molecules for targeting rpn11
EP3807263A1 (en) 2018-06-13 2021-04-21 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
CN112996518A (zh) * 2018-06-21 2021-06-18 西奈山伊坎医学院 Wd40重复结构域蛋白5(wdr5)降解/破坏化合物和使用方法
CN112714646A (zh) * 2018-07-05 2021-04-27 西奈山伊坎医学院 蛋白酪氨酸激酶6(ptk6)降解/破坏化合物和使用方法
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US11981618B2 (en) * 2018-07-24 2024-05-14 Autotac Inc. P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same
US20200038513A1 (en) * 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
CN112533898A (zh) 2018-07-31 2021-03-19 日商泛美克斯股份有限公司 杂环化合物
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
CN112888681A (zh) 2018-08-22 2021-06-01 上海睿跃生物科技有限公司 原肌球蛋白受体激酶(trk)降解化合物及使用方法
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
AU2019335516B2 (en) 2018-09-07 2022-06-16 Arvinas Operations, Inc. Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US20220047596A1 (en) * 2018-09-12 2022-02-17 Board Of Regents, The University Of Texas System Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer
JP2022501388A (ja) * 2018-09-19 2022-01-06 ラホヤ インスティチュート フォー イミュノロジー 関節リウマチにおけるｐｔｐｒｓ及びプロテオグリカン
KR20210077719A (ko) 2018-10-15 2021-06-25 누릭스 테라퓨틱스 인코포레이티드 유비퀴틴 프로테오좀 경로를 통해 btk를 분해시키기 위한 이작용성 화합물
CN113056287A (zh) * 2018-10-24 2021-06-29 豪夫迈·罗氏有限公司 缀合的化学降解诱导剂及使用方法
US20220001017A1 (en) * 2018-11-09 2022-01-06 Shanghai Qiangrui Biotech Co., Ltd. Micromolecular compound specificallydegrading tau protein, and application thereof
CN111171113B (zh) * 2018-11-09 2023-05-16 汪义朋 一种特异性降解tau蛋白的小分子化合物及其应用
CN111233661B (zh) * 2018-11-29 2023-03-31 暨南大学 靶向泛素化降解ERRα蛋白的化合物及其药用组合物和应用
JP2022516401A (ja) 2018-11-30 2022-02-28 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
SG11202106507RA (en) 2018-12-19 2021-07-29 Celgene Corp Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
KR20210118828A (ko) 2018-12-19 2021-10-01 셀진 코포레이션 치환된 3-((3-아미노페닐)아미노)피페리딘-2,6-디온 화합물, 이의 조성물, 및 이를 사용한 치료 방법
US11547759B2 (en) 2019-01-30 2023-01-10 Montelino Therapeutics, Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
EP3917916A4 (en) 2019-01-30 2022-12-14 Montelino Therapeutics, Inc. BIFUNCTIONAL COMPOUNDS AND METHODS FOR TARGETING ANDROGEN RECEPTOR UBIQUITINATION
EP3922632A4 (en) * 2019-02-07 2023-02-15 Korea Research Institute of Chemical Technology DEGRADATION AGENT THAT INDUCES DEGRADATION OF A TARGET EED PROTEIN, METHOD FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH EED, EZH2 OR PRC2 USING SUCH AGENT AS THE ACTIVE SUBSTANCE
WO2020168172A1 (en) * 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment
AU2020241903A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicle conjugates and uses thereof
EP3941607A1 (en) 2019-03-21 2022-01-26 Codiak BioSciences, Inc. Process for preparing extracellular vesicles
WO2020206424A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
BR112021019722A2 (pt) 2019-04-09 2021-12-14 Nurix Therapeutics Inc Compostos de piperidina 3-substituídos para inibição de cbl-b, e uso de inibidor de cbl-b em combinação com vacina contra câncer e/ou vírus oncolítico
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
AU2020272978A1 (en) 2019-04-12 2021-09-16 C4 Therapeutics, Inc. Tricyclic degraders of Ikaros and Aiolos
CA3132387A1 (en) * 2019-04-23 2020-10-29 Dana-Farber Cancer Institute, Inc. Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof
CN110151767B (zh) * 2019-05-08 2022-10-18 武汉威立得生物医药有限公司 Gnf-7在制备治疗流感病毒感染的药物中的应用
US11826430B2 (en) 2019-05-14 2023-11-28 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
JP2022533147A (ja) * 2019-05-17 2022-07-21 ヒノバ ファーマシューティカルズ インコーポレイテッド 芳香族アミン類のａｒ及びｂｅｔを標的とするタンパク質分解キメラ化合物及び使用
EP3969447A1 (en) 2019-05-17 2022-03-23 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for cbl-b inhibition and uses thereof
US20220233702A1 (en) * 2019-06-03 2022-07-28 Regents Of The University Of Minnesota Compounds that degrade kinases and uses thereof
US11890346B2 (en) 2019-06-12 2024-02-06 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein
EP3989966A4 (en) 2019-06-28 2023-09-27 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US20220281876A1 (en) * 2019-07-26 2022-09-08 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
EP4010336A4 (en) * 2019-08-05 2023-08-23 Dana-Farber Cancer Institute, Inc. CYCLIN-DEPENDENT KINASE 7 (CDK7) DEGRADING AGENTS AND THEIR USES
EP4038066A1 (en) 2019-10-01 2022-08-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
IL292387A (en) 2019-10-23 2022-06-01 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis A chimeric polypeptide for immune cell regulation
WO2021078301A1 (zh) * 2019-10-24 2021-04-29 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CN110713480B (zh) * 2019-10-28 2021-02-26 浙江省医学科学院 AChE蛋白降解物及其制备方法和应用
CN110684022B (zh) * 2019-11-01 2022-07-08 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其中间体、制备方法和用途
CN110759902B (zh) * 2019-11-01 2022-04-22 海南一龄医疗产业发展有限公司 Set8赖氨酸甲基转移酶抑制剂及其制备方法和用途
EP4054546A4 (en) * 2019-11-06 2023-10-18 Dana-Farber Cancer Institute, Inc. SELECTIVE HISTONE DEACETYLASE (HDAC) DEGRADATION PRODUCTS AND METHOD FOR THE USE THEREOF
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
EP4069676A1 (en) 2019-12-04 2022-10-12 Omeros Corporation Masp-2 inhibitors and methods of use
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
JP2023504147A (ja) 2019-12-04 2023-02-01 ニューリックス セラピューティクス，インコーポレイテッド ユビキチンプロテオソーム経路を介したｂｔｋの分解のための二官能性化合物
US11904006B2 (en) 2019-12-11 2024-02-20 University Of Iowa Research Foundation Poly(diaminosulfide) particle-based vaccine
CN112979747A (zh) * 2019-12-16 2021-06-18 江苏恒瑞医药股份有限公司 用于制备蛋白降解靶向嵌合体的羟脯氨酸衍生物
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
US11883393B2 (en) 2019-12-19 2024-01-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP4076450A4 (en) 2019-12-20 2024-01-10 C4 Therapeutics, Inc. ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR DEGRADING EGFR
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
JP2023516645A (ja) * 2020-03-04 2023-04-20 ジェネンテック， インコーポレイテッド Ｔｅａｄ阻害剤としてのヘテロ二官能性分子
CA3165309A1 (en) 2020-03-05 2021-09-10 Christopher G. Nasveschuk Compounds for targeted degradation of brd9
TW202200543A (zh) 2020-03-19 2022-01-01 美商凱麥拉醫療公司 Mdm2降解劑及其用途
KR20230004511A (ko) 2020-03-21 2023-01-06 아비나스 오퍼레이션스, 인코포레이티드 인다졸계 화합물 및 관련된 사용 방법
WO2021194878A1 (en) 2020-03-21 2021-09-30 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
KR102337029B1 (ko) 2020-03-27 2021-12-09 (주) 업테라 Plk1 선택적 분해 유도 화합물
CN115298173A (zh) * 2020-03-31 2022-11-04 田边三菱制药株式会社 羟基吡咯烷衍生物及其医药用途
CN115803030A (zh) 2020-04-06 2023-03-14 阿维纳斯企业公司 用于kras靶向降解的化合物和方法
CA3176547A1 (en) * 2020-04-23 2021-10-28 Milad ROUHIMOGHADAM Gper proteolytic targeting chimeras
US20240270780A1 (en) * 2020-04-29 2024-08-15 Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd Proteolysis targeting compound with tissue targeting capability and use thereof
PE20231204A1 (es) 2020-05-09 2023-08-17 Arvinas Operations Inc Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo
CN111606969B (zh) * 2020-05-13 2023-02-03 四川大学 一种parp1蛋白降解剂及其在抗肿瘤中的应用
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
US20230183197A1 (en) * 2020-06-01 2023-06-15 Neophore Limited Inhibitors of mlh1 and/or pms2 for cancer treatment
CN113321700B (zh) * 2020-06-02 2022-07-01 泰比瑞医药科技(石家庄)有限公司 一种降解靶蛋白的双功能化合物及其用途
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2022047145A1 (en) 2020-08-28 2022-03-03 Arvinas Operations, Inc. Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
US20240241020A1 (en) 2020-09-23 2024-07-18 Lonza Sales Ag Process for preparing extracellular vesicles
WO2022087125A1 (en) 2020-10-21 2022-04-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor protein
CN112174999A (zh) * 2020-11-02 2021-01-05 兰州理工大学 一种具有抗癌活性的钛金属配合物后修饰产物及其制备方法与应用
US20220144809A1 (en) 2020-11-06 2022-05-12 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor and associated methods of use
CA3197092A1 (en) * 2020-11-11 2022-05-19 Jakob FUHRMANN 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
AR124189A1 (es) * 2020-11-30 2023-02-22 Genentech Inc Compuestos y procedimientos de uso de los mismos
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
WO2022169780A1 (en) 2021-02-02 2022-08-11 Les Laboratoires Servier Selective bcl-xl protac compounds and methods of use
BR112023015067A2 (pt) 2021-02-15 2023-10-03 Astellas Pharma Inc Composto de quinazolina para induzir a degradação de proteína kras g12d mutante
WO2022187650A1 (en) * 2021-03-04 2022-09-09 The Scripps Research Institute Heterobifunctional compositions for targeted protein degradation and methods for their use
US20240159737A1 (en) * 2021-03-09 2024-05-16 Baylor College Of Medicine Cellular selectivity profiling against rna helicases and splicing regulators
CN115043817A (zh) * 2021-03-09 2022-09-13 苏州泽璟生物制药股份有限公司 Sos1蛋白水解调节剂及其制备方法和应用
AU2022238476A1 (en) 2021-03-19 2023-10-05 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
MX2023011241A (es) 2021-03-23 2023-10-03 Nuvation Bio Inc Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
CA3214729A1 (en) 2021-04-08 2022-10-13 Marilena GALLOTTA Combination therapies with cbl-b inhibitor compounds
MX2023011940A (es) 2021-04-16 2023-12-07 Arvinas Operations Inc Moduladores de la proteolisis bcl6 y metodos de uso asociados.
CN115232111A (zh) * 2021-04-23 2022-10-25 上海领泰生物医药科技有限公司 Sos1降解剂及其制备方法和应用
CN113603676B (zh) * 2021-04-28 2022-05-24 浙江工业大学 基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
EP4334360A2 (en) 2021-05-03 2024-03-13 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
CA3218577A1 (en) 2021-05-03 2022-11-10 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
EP4089103A1 (en) 2021-05-12 2022-11-16 Universität Duisburg-Essen Clpcp protease-binding cyclic heptapeptides
WO2022266258A1 (en) 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023034411A1 (en) 2021-09-01 2023-03-09 Oerth Bio Llc Compositions and methods for targeted degradation of proteins in a plant cell
US11981672B2 (en) 2021-09-13 2024-05-14 Montelino Therapeutics Inc. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス， インコーポレイテッド Ｔｙｋ２分解剤およびそれらの使用
CN118574827A (zh) 2021-11-24 2024-08-30 阿维纳斯运营公司 Brm靶向化合物和相关的使用方法
EP4436966A1 (en) 2021-11-24 2024-10-02 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
GB202117225D0 (en) * 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
CN113979999B (zh) * 2021-12-23 2022-05-20 北京鑫开元医药科技有限公司 靶向泛素化降解bcr-abl激酶的化合物及其制备方法、组合物和用途
WO2023119677A1 (en) 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
WO2023141570A2 (en) * 2022-01-21 2023-07-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of kras
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
TW202339738A (zh) 2022-01-31 2023-10-16 美商凱麥拉醫療公司 Irak降解物及其用途
CN116676273A (zh) * 2022-02-22 2023-09-01 中国科学院深圳先进技术研究院 一种蛋白水解靶向流感病毒及其制备方法和应用
WO2023171781A1 (ja) 2022-03-11 2023-09-14 アステラス製薬株式会社 Ｇ１２ｄ変異ｋｒａｓタンパクの分解を誘導するための複素環化合物
CN114560908B (zh) * 2022-03-11 2024-10-25 国家纳米科学中心 一种多肽protac分子及其制备方法和应用
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
WO2023220425A1 (en) * 2022-05-12 2023-11-16 Kymera Therapeutics, Inc. Bcl-xl/bcl-2 degraders and uses thereof
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
TW202417425A (zh) 2022-06-27 2024-05-01 美商傳達治療有限公司 雌激素受體α降解劑及其使用方法
WO2024020221A1 (en) 2022-07-21 2024-01-25 Arvinas Operations, Inc. Modulators of tyk2 proteolysis and associated methods of use
WO2024035780A1 (en) * 2022-08-09 2024-02-15 Board Of Regents Of The University Of Nebraska Akr1c3 targeted heterobifunctional small molecule proteolysis targeting chimeras
CN115028679B (zh) * 2022-08-11 2022-11-15 深圳湾实验室 一种具有Cyclophilin A降解活性的PROTAC化合物及其制备方法与应用
WO2024033538A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024033537A1 (en) 2022-08-12 2024-02-15 Astellas Pharma Inc. Combination of anticancer agents comprising a bifunctional compound with g12d mutant kras inhibitory activity
WO2024039210A1 (ko) * 2022-08-17 2024-02-22 한국화학연구원 Cdk2 및/또는 cdk9의 억제 또는 분해용 화합물 및 이들의 의약 용도
WO2024040080A1 (en) * 2022-08-19 2024-02-22 Erasca, Inc. Kras inhibitor conjugates
CN115475164B (zh) * 2022-08-22 2024-06-04 西安交通大学 一种可降解PDGFR-β的蛋白降解靶向嵌合体及其制备方法和应用
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024064358A1 (en) 2022-09-23 2024-03-28 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024081913A1 (en) * 2022-10-14 2024-04-18 76Bio, Inc. Dual-specific bifunctional fusion proteins for ubiquitin-mediated degradation
WO2024127297A1 (en) 2022-12-16 2024-06-20 Pfizer Inc. 3-fluoro-4-hydroxybenzmide-containing inhibitors and/or degraders and uses thereof
EP4428134A1 (en) 2023-03-10 2024-09-11 Dark Blue Therapeutics Ltd Protac degraders of mllt1 and/or mllt3
US20240335444A1 (en) 2023-01-09 2024-10-10 Arvinas Operations, Inc. Modulators of bcl6 proteolysis and associated methods of use
US20240287101A1 (en) 2023-01-26 2024-08-29 Arvinas Operations, Inc. Cereblon-based kras degrading protacs and uses related thereto
CN117024413B (zh) * 2023-10-07 2024-01-09 天津匠新致成科技有限公司 3-氨基吡嗪-2-甲酰胺类靶向蛋白水解嵌合体及其制备方法、药物组合物和应用
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物
CN118515785B (zh) * 2024-07-24 2024-11-08 上海青煜医药科技有限公司 融合蛋白、包含其的泛素化系统及其应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2116591T3 (es) 1993-04-07 1998-07-16 Pfizer Cicloalquilhidroxiureas y su uso como inhibidores de la lipoxigenasa.
DE69705838T2 (de) * 1996-04-24 2002-04-11 Medivir Uk Ltd., Cambridge Substrate und inhibitoren von proteolytischen enzymen
CA2204082A1 (en) * 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6218425B1 (en) * 1996-08-06 2001-04-17 Eli Lilly And Company 8-substituted B-nor-6-Thiaequilenin compounds having activity as selective estrogen receptor modulators
CA2218756A1 (en) * 1996-10-25 1998-04-25 Kristin Sue Marron Substituted benzo¢b!thiophene compounds having activity as selective estrogen receptor modulators
HRP970566A2 (en) 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser
ATE460423T1 (de) 1997-05-14 2010-03-15 Sloan Kettering Inst Cancer Verfahren und zubereitungen zur zerstörung bestimmter proteine
AU740597B2 (en) 1997-07-10 2001-11-08 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US7223556B1 (en) 1998-10-09 2007-05-29 President And Fellows Of Harvard College Targeted proteolysis by recruitment to ubiquitin protein ligases
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
EP1155030A4 (en) * 1999-02-26 2005-12-14 Oklahoma Med Res Found NEW COMPOUND VON HIPPEL-LINDAU TUMOR SUPPRESSOR COMPLEX AND SCF UBIQUITIN LIGASE
EP1176959B1 (en) 1999-05-05 2006-03-08 Merck & Co., Inc. Novel prolines as antimicrobial agents
US6552166B1 (en) 1999-10-19 2003-04-22 Merck & Co., Inc. Process for the preparation of conjugates useful in the treatment of prostate cancer
US6740495B1 (en) * 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
WO2002000617A2 (en) * 2000-06-28 2002-01-03 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
CN1230418C (zh) * 2000-08-24 2005-12-07 田纳西大学研究公司 选择性雄激素受体调节剂及其使用方法
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
AU2001295041A1 (en) 2000-09-08 2002-03-22 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
JP2005507363A (ja) 2001-02-16 2005-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 血管新生阻害トリペプチド、組成物およびそれらの使用方法
HN2002000136A (es) * 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
ATE491701T1 (de) * 2001-08-03 2011-01-15 Vertex Pharma Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung
US20030133927A1 (en) 2001-10-10 2003-07-17 Defeo-Jones Deborah Conjugates useful in the treatment of prostate cancer
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US7053046B2 (en) 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
US20030143590A1 (en) 2002-11-18 2003-07-31 Shyam Ramakrishnan Regulation of human dopamine-like g protein- coupled receptor
US7915293B2 (en) * 2003-05-30 2011-03-29 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN1835937B (zh) * 2003-06-13 2012-07-18 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的噻唑啉衍生物
WO2005111028A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
WO2006006065A1 (en) 2004-07-08 2006-01-19 Warner-Lambert Company Llc Androgen modulators
DE102008020113A1 (de) 2008-04-23 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituierte Dihydropyrazolone und ihre Verwendung
US20060167066A1 (en) 2004-12-20 2006-07-27 Genentech, Inc. Pyrrolidine inhibitors of IAP
US20060252698A1 (en) * 2005-04-20 2006-11-09 Malcolm Bruce A Compounds for inhibiting cathepsin activity
US7718846B2 (en) 2005-05-16 2010-05-18 Gideon Koren Animal models of long QT syndrome and uses thereof
CA2620414A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
JP5175191B2 (ja) 2005-08-30 2013-04-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グリコピラノシル置換ベンジルベンゼン誘導体、該化合物を含有する医薬品及びその使用と製造方法
CN101410381B (zh) * 2006-01-24 2011-08-03 詹森药业有限公司 作为选择性雄激素受体调节剂(sarms)的2-取代的苯并咪唑
CA2643267A1 (en) 2006-03-03 2007-09-20 Novartis Ag N-formyl hydroxylamine compounds
US7989487B2 (en) * 2006-07-06 2011-08-02 University Of Medicine And Dentistry Of New Jersey Estrogen receptor modulators and uses thereof
WO2008011392A2 (en) * 2006-07-20 2008-01-24 Ligand Pharmacueticals Incorporated Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
US8518891B2 (en) 2006-11-29 2013-08-27 Longqin Hu Chemotherapeutic conjugates and methods of use
US20080233850A1 (en) * 2007-03-20 2008-09-25 3M Innovative Properties Company Abrasive article and method of making and using the same
CL2008001234A1 (es) 2007-04-30 2008-09-22 Genentech Inc Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
US8415340B2 (en) * 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
KR101595238B1 (ko) * 2007-12-21 2016-02-18 리간드 파마슈티칼스 인코포레이티드 선택적 안드로겐 수용체 조절제(ｓａｒｍ) 및 이의 용도
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
WO2010027564A2 (en) 2008-07-18 2010-03-11 Glaxosmithkline Llc Amido anti-viral compounds, compositions, and methods of use
CN101768155B (zh) 2008-12-30 2012-09-05 天津药物研究院 一类含(氨甲基-五元芳香杂环-4-羰基)-吡咯烷-2-羧酸的衍生物、其制备方法和用途
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
WO2010141805A1 (en) * 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heterocyclic amides as modulators of trpa1
WO2011005510A2 (en) * 2009-06-22 2011-01-13 Cerapedics, Inc. Peptide conjugates and uses thereof
CN102510755A (zh) 2009-07-13 2012-06-20 哈佛大学校长及研究员协会 双功能钉接多肽和其用途
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110164191A1 (en) * 2010-01-04 2011-07-07 Microvision, Inc. Interactive Projection Method, Apparatus and System
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 白血病を治療するための組成物および方法
DK2571503T3 (en) 2010-05-14 2015-04-20 Dana Farber Cancer Inst Inc COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS
WO2011160016A2 (en) * 2010-06-17 2011-12-22 The Trustees Of Columbia University In The City Of New York E3 binding pockets and identification and use of e3 ligase inhibitors
EP2588129A4 (en) * 2010-06-30 2014-07-09 Univ Brandeis ON SMALL MOLECULES TARGETED PROTEIN REMOVAL
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス，インコーポレーテッド リン酸輸送を阻害する化合物及び方法
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
US8809377B2 (en) 2010-09-24 2014-08-19 The Regents Of The University Of Michigan Deubiquitinase inhibitors and methods for use of the same
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CA2823837A1 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
WO2012090104A1 (en) 2010-12-31 2012-07-05 Kareus Therapeutics, Sa Methods and compositions for designing novel conjugate therapeutics
EP2696682B1 (en) 2011-04-13 2018-03-21 Innovimmune Biotherapeutics, Inc. Mif inhibitors and their uses
RU2666530C2 (ru) 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US20150119435A1 (en) 2012-05-11 2015-04-30 Yale University Compounds useful for promoting protein degradation and methods using same
AU2013283378B2 (en) 2012-06-25 2017-07-13 Oncoethix Gmbh Method of treating lymphoma using thienotriazolodiazepine compounds
KR101738063B1 (ko) 2012-09-21 2017-05-19 아로그 파마슈티칼스, 인코퍼레이티드 구조적으로 활성인 인산화된 ｆｌｔ３ 키나제의 억제 방법
GB201311910D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
NL2011274C2 (en) 2013-08-06 2015-02-09 Illumicare Ip B V 51 Groundbreaking platform technology for specific binding to necrotic cells.
EP2958923A1 (de) 2013-02-22 2015-12-30 Bayer Pharma Aktiengesellschaft 4-substituierte pyrrolo- und pyrazolo-diazepine
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) * 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
NZ720004A (en) 2013-11-18 2020-03-27 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
RU2738833C9 (ru) 2014-04-14 2022-02-28 Арвинас, Оперэйшнз, Инк. Имидные модуляторы протеолиза и способы их применения
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3201199A1 (en) 2014-10-02 2017-08-09 Glaxosmithkline Intellectual Property (No. 2) Limited Compound
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
EP3247708A4 (en) 2015-01-20 2018-09-12 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
GB201504314D0 (en) 2015-03-13 2015-04-29 Univ Dundee Small molecules
EP4414369A3 (en) 2015-03-18 2024-10-16 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
CN108366992A (zh) * 2015-11-02 2018-08-03 耶鲁大学 蛋白水解靶向嵌合体化合物及其制备和应用方法

Also Published As

Publication number Publication date
RU2018126714A (ru) 2019-03-12
WO2013106643A2 (en) 2013-07-18
KR102438072B1 (ko) 2022-08-31
AU2013207900A1 (en) 2014-07-24
JP2023171589A (ja) 2023-12-01
EP2802608A2 (en) 2014-11-19
EP2802608A4 (en) 2015-08-05
KR20240096553A (ko) 2024-06-26
CA2861066A1 (en) 2013-07-18
AU2020239664A1 (en) 2020-10-15
EP3608317A1 (en) 2020-02-12
KR102204989B1 (ko) 2021-01-20
MX2022009478A (es) 2022-10-10
JP2020063314A (ja) 2020-04-23
WO2013106643A3 (en) 2013-09-06
RU2014133019A (ru) 2016-02-27
US20190127359A1 (en) 2019-05-02
KR20200063135A (ko) 2020-06-04
KR20150010935A (ko) 2015-01-29
RU2018126714A3 (ja) 2021-10-14
MX358660B (es) 2018-08-30
CN104736569A (zh) 2015-06-24
JP2021185202A (ja) 2021-12-09
BR112014017095A2 (pt) 2017-06-13
AU2013207900B2 (en) 2017-12-07
KR20220124816A (ko) 2022-09-14
AU2020239664B2 (en) 2022-04-21
CN117736134A (zh) 2024-03-22
AU2018201554A1 (en) 2018-03-29
AU2013207900A8 (en) 2014-07-31
JP2015508414A (ja) 2015-03-19
US20140356322A1 (en) 2014-12-04
US20240317729A1 (en) 2024-09-26
AU2018201554B2 (en) 2020-06-25
JP2019023206A (ja) 2019-02-14
CA2861066C (en) 2024-01-02
US10730862B2 (en) 2020-08-04
AU2022205187A1 (en) 2022-07-28
AU2022205187B2 (en) 2024-04-04
MX2014008520A (es) 2015-08-14
RU2666530C2 (ru) 2018-09-11
AU2024201732A1 (en) 2024-04-11
KR102668696B1 (ko) 2024-05-29

Similar Documents

Publication Publication Date Title
HK1208875A1 (en) Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase e3
HK1210191A1 (en) Methods for the manufacture of proteolytically processed polypeptides
HK1220233A1 (zh) 用於神經變性疾病的細胞性發現平台
HK1217731A1 (zh) 異源二聚化多肽
HK1200466A1 (en) Method for the preparation of surfactant peptides
EP2728002A4 (en) HETERODIMIZED POLYPEPTIDE
PT2677029T (pt) Métodos para o fabrico de polipéptidos processados proteoliticamente
EP3257519B8 (en) Ccr2 antagonist peptides
EP3067367A4 (en) Method for purifying recombinant protein
EP2867154A4 (en) ADVANCED RESONATOR
ZA201500228B (en) Ctla4 fusion proteins for the treatment of diabetes
SG10201501080VA (en) Method For The Determination Of Sequence Variants Of Polypeptides
HK1207120A1 (en) Improved harvest operations for recombinant proteins
EP2812349A4 (en) METHOD FOR CHARACTERIZING INTERACTION RANGES IN TARGET PROTEINS
IL238627B (en) Peptides containing a sequence derived from fviii
HK1204948A1 (en) Radiation-sterilization-resistant protein composition
IL235052B (en) A method for increasing the secretion of recombinant proteins
EP2920206A4 (en) MODIFIED APOL1 POLYPEPTIDES
HK1211952A1 (en) Recombinant protein
GB201200743D0 (en) Protein bridges
EP2826820A4 (en) RESIN COMPOSITION FOR LASER TREATMENT
GB201112985D0 (en) Polypeptide
GB201112849D0 (en) Polypeptide
GB201106130D0 (en) Polypeptide
AU2011900664A0 (en) Method for inhibiting proteins